What is the recommended systemic therapy and management for metastatic mucinous adenocarcinoma of the appendix?

Recommended Systemic Therapy for Metastatic Mucinous Adenocarcinoma of the Appendix

For metastatic mucinous adenocarcinoma of the appendix, fluoropyrimidine-based doublet chemotherapy regimens (FOLFOX or FOLFIRI) should be offered as first-line systemic therapy, following the treatment paradigm for metastatic colorectal cancer, with consideration of molecular profiling to guide targeted therapy selection.

Treatment Framework

Since appendiceal adenocarcinomas lack dedicated guidelines, management follows metastatic colorectal cancer (mCRC) protocols as recommended by NCCN and ASCO 1, 2. However, critical distinctions exist based on tumor grade and resectability status.

First-Line Systemic Therapy

Fluoropyrimidine-based doublet regimens are the standard approach:

• FOLFOX (fluoropyrimidine + oxaliplatin) or FOLFIRI (fluoropyrimidine + irinotecan) represent preferred first-line options 1, 2
• Recent data from Australia showed fluoropyrimidine-based doublets achieved a 39.4% objective response rate in metastatic appendiceal adenocarcinoma 3
• Irinotecan-based regimens may offer superior outcomes: median OS of 66.4 months vs 21.6 months with oxaliplatin-based regimens, though this requires prospective validation 3

Molecular Profiling and Targeted Therapy

Molecular testing should guide treatment selection:

• RAS mutations are present in approximately 68.6% of appendiceal adenocarcinomas 3
• For RAS wild-type, left-sided tumors: add anti-EGFR therapy (cetuximab or panitumumab) to chemotherapy 2
• For RAS wild-type, right-sided tumors: add bevacizumab (anti-VEGF therapy) to chemotherapy 2
• For BRAF V600E mutations: encorafenib plus cetuximab after progression on first-line therapy 2
• MSI-H/dMMR tumors: pembrolizumab monotherapy is preferred first-line 2

Critical Grade-Specific Considerations

Low-Grade Mucinous Adenocarcinoma

Systemic chemotherapy provides NO survival benefit and may cause harm in low-grade disease:

• Multiple studies demonstrate no OS improvement with chemotherapy in low-grade appendiceal mucinous adenocarcinoma 4
• Adding systemic chemotherapy to CRS/HIPEC worsens survival (HR 2.77) in low-grade disease, likely by delaying definitive surgical intervention 5
• If CRS/HIPEC is planned, proceed directly to surgery without neoadjuvant chemotherapy 5
• 5-year OS is 52.9% without chemotherapy vs 61.3% with chemotherapy (not statistically significant) 4

High-Grade and Intermediate-Grade Disease

Systemic chemotherapy is appropriate for higher-grade tumors:

• Standard doublet chemotherapy regimens should be offered 1, 2
• Consider triplet therapy (FOLFOXIRI) for fit patients with high disease burden 2
• Bevacizumab addition showed no clear survival benefit in recent appendiceal-specific data 3

Surgical Considerations

Surgery remains the cornerstone of treatment when feasible:

• CRS + HIPEC is standard for resectable peritoneal metastases 2
• Do NOT add hyperthermic intraperitoneal chemotherapy (HIPEC) to standard systemic chemotherapy - ASCO explicitly recommends against this combination 2
• For non-mucinous subtypes undergoing CRS/HIPEC, additional systemic chemotherapy beyond HIPEC provides no survival benefit 6
• Perioperative chemotherapy or surgery alone for potentially curative liver metastasis resection 2

Treatment Algorithm

1. Obtain molecular profiling: RAS, BRAF, MSI/MMR status 2, 3
2. Determine histologic grade: Low vs intermediate/high-grade
3. Assess resectability: Evaluate for CRS/HIPEC candidacy

If low-grade + resectable peritoneal disease:

• Proceed directly to CRS/HIPEC without neoadjuvant chemotherapy 5

If high/intermediate-grade OR unresectable:

• Start fluoropyrimidine-based doublet chemotherapy 1, 2, 3
• Add targeted therapy based on molecular profile and sidedness 2
• Consider irinotecan-based regimens over oxaliplatin-based given emerging survival data 3

If MSI-H/dMMR:

• Use pembrolizumab monotherapy first-line 2

Prognostic Factors

Factors associated with worse survival include:

• Male sex 3
• Elevated CEA levels 3
• Overweight/obesity 3
• Peritoneal carcinomatosis index >10 7
• Goblet cell and signet ring cell subtypes 7

Common Pitfalls

• Do not delay surgery for neoadjuvant chemotherapy in low-grade disease - this worsens outcomes 5
• Do not treat all appendiceal adenocarcinomas uniformly - grade-specific approaches are essential 4
• Do not assume bevacizumab improves outcomes - recent appendiceal-specific data shows no clear benefit 3
• Do not add routine systemic chemotherapy to CRS/HIPEC in non-mucinous subtypes 6